ArticleDiscover oncology2025
Evolution of glioma exosome research: emerging trends and global collaborations (2005-2025).
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The updated role of exosomes in cancer diagnosis and therapy.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlioma, a tumor derived from neuroglial cells of the central nervous system, is characterized by its high malignancy, frequent recurrence, and high mortality rate. Recent advances in exosome research related to gliomas have propelled this emerging field as a pivotal area of clinical neuroscience investigation. Despite extensive focus on glioma exosome research, a systematic visual analysis of this field remains lacking. Using bibliometric analysis, this study maps the scientific landscape of glioma exosome research to identify current hotspots and emerging trends in neuro-oncology.
methodsThis bibliometric analysis extracted glioma exosome publications from the Web of Science Core Collection(WoSCC) spanning 2005-2025. Following systematic screening, 209 articles constituted the analytic corpus. Using VOSviewer(VOS), Scimago Graphica, and CiteSpace, we mapped contributions across geographic, institutional, authorship, and conceptual domains. This visualization delineates the field's intellectual structure, identifies current research foci, and projects emerging trends in neuro-oncology.
resultsAnnual publication volume on glioma exosomes has increased significantly since 2019. China and the United States are the predominant contributors, collectively driving field advancement. Leading institutions include Shandong University, Shandong Provincial Key Laboratory of Brain Function Reconstruction, and Capital Medical University, whose productivity metrics reflect substantial influence. Notably, Chinese institutions comprise 90% of the top 10 productive entities. Key investigators Li Gang and Xue Hao demonstrate exceptional scholarly output, advancing the field through high-impact research. NEURO-ONCOLOGY emerges as the premier journal, evidenced by its dominant citation frequency. Thematic analysis reveals three conceptual domains: Exosome biogenesis in gliomas, Glioblastoma extracellular vesicle signatures, and Exosome mediated drug delivery systems-representing current priorities and evolving research frontiers.
conclusionExosomes have attracted considerable attention in glioma research, establishing themselves as a cutting edge thematic focus. This study applies bibliometric rigor to map research trajectories and conceptual evolution in glioma exosomes. The analysis establishes foundational frameworks that prioritize future investigation domains while objectively quantifying the field's translational potential. These evidence-based insights will accelerate mechanistic discovery and clinical translation in neuro-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.